VentureBeat

Kapow Technologies, which sells software to companies that lets them assemble their own “mashup” applications by gathering data from around the web, has raised a $11.6 million third round of financing.

Mashup technologies have become increasingly important lately, now that data has proliferated around the Web and new technologies such as RSS allow people to pipe it directly to their computers, versus having to go get it themselves. A research analyst covering the retail sector, for example, no longer has to go visit the Victoria Secret web site to scour it for data and paste it into their spreadsheet. Now she can create a feed from Victoria Secret and all other major retailers, and have it all sync in a single spreadsheet within her Kapow dashboard.

Kapow, based in Palo Alto, Calif., lets her also configure a way to gather data from other places, such as internal enterprise resource planning (ERP) application or database that might be behind a corporate firewall. She can then mash it all up into whatever application format she wants.

Even if a site doesn’t provide an RSS feed, Kapow can create an RSS feed by using a robot to crawl the site. Kapow then relies on an application like Excel to allow you to pull it all together, or other receptor applications provided by companies like IBM and Serena. Kapow can even deliver it to your mobile phone.

Other companies doing something similar are Dapper, but that company has been less focused on serving large companies, more focused on consumers.

There are an array of other mashup companies, for example other mashup interface makers, such as Backface and Jackbe, but they too focus less on actually gathering data from other places, and more on helping you do the mashup application itself. Other companies, such as Connotate, provide a mashup service to automate the process for you, relying on outsourced help, and providing less customizable features.

Kapow says customers include Wells Fargo, Bank of America and Credit Suisse Boston, and that some 3,000 companies have installed the technology worldwide.

New investors include Steamboat Ventures, a venture capital firm affiliated with The Walt Disney Company, and Morgan Stanley’s Strategic Investments Group. Previous investors Kennet Partners and NorthCap Partners also participated in the round.

Featured companies: Aldagen, LDR, Lyten Endoscopy, MachLabs, Permatox, TeleMedicine Clinic, ThromboVision

Spinal-implant maker LDR raises $25M — Austin, Texas-based LDR, a maker of spinal implants, raised $25 million in a third funding round. Investors included Telegraph Hill Partners, Austin Ventures, Rothschild Private Equity and PTV Sciences.

LDR sells spinal-fusion devices, artificial disks and other spine-related devices in more than 30 countries, and plans to use the funds for further expansion.

Aldagen adds $9M for adult stem-cell work — Aldagen, a Durham, N.C., biotech developing regenerative therapies with “adult” stem cells, raised an additional $9 million (PDF link), bringing its third funding round to a total of $23 million. Investors in the additional financing include Tullis-Dickerson, CNF Investments, Harbert Venture Partners and Intersouth Partners.

The company’s most advanced experimental treatment uses stem cells derived from umbilical-cord blood to somehow improve the speed and effectiveness of cord-blood transplants in children, although the company doesn’t explain how. Nor has it revealed the results of an early-stage human test. Other treatments now entering clinical trials use stem or related progenitor cells isolated from a patient’s own bone marrow to treat heart failure or clot-related oxygen deprivation in the limbs.

The Triangle Business Journal has more.

ThromboVision raises $4M for personalized-medicine diagnostics — The Houston, Texas, biotech ThromboVision said it raised $4 million in a first funding round. Investors included the private-equity firm National Healthcare Services and private investors.

ThromboVision is developing new tests of platelet activity that may help doctors determine which patients are most likely to respond to low doses of blood thinners such as aspirin or Plavix, which are used to prevent clots that can cause heart attacks or strokes. This is similar — in concept, at least — to the FDA’s recent push to require the use of genomic tests to determine the proper dosing of warfarin, another blood thinner. (See our coverage here.)

MachLabs launches two device companies — MachLabs, a Redwood City, Calif., investor partnership founded by entrepreneurs Michael Laufer and John Lonergan, recently launched two medical-device startups, VentureWire reports (subscription required). Lyten is developing a minimally invasive treatment for obesity, while Permatox hopes to introduce a non-invasive alternative to Botox.

TeleMedicine Clinic receives €7M for radiology services — Barcelona-based TeleMedicine Clinic, a center for the outsourced analysis of medical images such as X-rays and MRIs, raised €7 million ($9.7 million), VentureWire reports. Investors included Kennet Partners, Active Capital Partners and an undisclosed European seed investor.